We have to put aside a large number of vials for stability testing over the next 5 years (you need to test your drug batch every 6 months). The number of patients that can be treated is a really rough and conservative number as we don't know the final dose of bisantrene that will be possible to use in combination with doxorubicin, nor how many cycles each patient will get.
The bottom line is there is more than enough RC220 to treat all the patients in the Phase 1 & 2 clinical trials we have planned at this stage.
Ann: RC220 cGMP Manufacturing Complete, page-40
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |